PSMA is commonly used as a target for prostate cancer imaging and drug delivery.117, 118, 119, 120, 121 As boron-containing inhibitors generally had high binding affinity to PSMA, Flavell and co-workers combined PSMA inhibitor scaffolds with boric acids/carborane derivatives, delivering boron into prostate cancer cells and prostate tumor xenograft models (20, Figure 3L).119. Here, FOLH1 is linked to prostate carcinoma.